A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome

NCT00578825 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

340

Enrollment

OTHER_GOV

Sponsor class

Conditions

Severe Acute Respiratory Syndrome

Interventions

DRUG: Lopinavir / Ritonavir plus Ribavirin

Sponsor

Hospital Authority, Hong Kong